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Abstract
Mutated versions of membrane proteins often fail to express at the plasma membrane, but instead are
trapped in the secretory pathway, resulting in disease. The retention of these mutant proteins is thought
to result from local misfolding, which prevents export from the ER (endoplasmic reticulum), targeting
the receptor for degradation via the ER-associated quality control system. The rhodopsin-like G-protein-
coupled MC4R (melanocortin 4 receptor) is an example of such a membrane protein. Over 100 natural MC4R
mutations are linked with an obese phenotype and to date represent the most common monogenic cause
of severe early-onset obesity. More than 80% of these mutations result in a substantial proportion of MC4R
being retained intracellularly. If these receptors were expressed at the plasma membrane, many could
be functional, as mutations often occur in regions distinct from those associated with ligand or G-protein
binding. Our aim is to show proof of concept that selective compounds can rescue the function of MC4R
mutants by increasing their cell-surface expression, and further to this, examine whether the rescue profile
differs between mutants. Whole-cell ELISA and 96-well fluorescence-based assays with N-terminally HA
(haemagglutinin)-tagged and C-terminally mCherry-tagged mutant MC4Rs were used to screen a number of
novel MC4R-selective compounds. A total of four related compounds increased the cell-surface expression
of wild-type and three intracellularly retained mutant MC4Rs, thus acting as pharmacological chaperones.
There appears to be a unique rescue efficacy profile for each compound that does not correlate with potency,
suggesting distinct receptor conformations induced by the different mutations. A degree of functionality of
V50M and S58C was also rescued following relocation to the cell surface.
Introduction
Several obesity-causing mutant MC4Rs (melanocortin 4
receptors) have been studied in detail with respect to their
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cellular localization, and subsequent ligand binding and
signalling capabilities [1,2], suggesting that approximately
80% of mutations in MC4R found in early-onset obesity
result in reduced plasma membrane expression [3]. Similar to
many other naturally occurring point mutations in GPCRs
(G-protein-coupled receptors), the intracellular retention
is thought to be a result of the cellular chaperone-
mediated quality control machinery detecting an aberrant
fold and clearing the misfolded proteins by the ERAD
[ER (endoplasmic reticulum)-associated degradation] system
[4]. Interestingly, the degree of severity of intracellular
retention of thesemutations can vary, with some being almost
Biochem. Soc. Trans. (2012) 40, 717–720; doi:10.1042/BST20110764 C©The Authors Journal compilation C©2012 Biochemical Society 717B
io
ch
em
ic
al
 S
oc
ie
ty
 T
ra
ns
ac
tio
ns
   
  w
w
w
.b
io
ch
em
so
ct
ra
ns
.o
rg
718 Biochemical Society Transactions (2012) Volume 40, part 4
Figure 1 Novel MC4R antagonists rescue the cell-surface expression of MC4R mutants V50M, S58C and I137T
(A) Compound A, (B) Compound B, (C) Compound C and (D) Compound D. Cell-surface expression is expressed as a
percentage of basal wild-type. Results are means ± S.E.M. (n = 3 performed in triplicate). ***P < 0.0005 and ****P < 0.0001
(Student’s t test) compared with basal conditions of each receptor.
completely absent from the plasma membrane, whereas
others retain significant cell-surface expression [5,6]. The
ability to rescue the function of these mutations could be of
significant therapeutic value in the treatment of severe early-
onset obesity.
Evaluation of pharmacological chaperone
action
Wild-type and mutant human MC4R were tagged with an
N-terminal HA (haemagglutinin) epitope and a C-terminal
mCherry fluorescent protein and transiently expressed in
HEK (human embryonic kidney)-293 cells. Relative plasma
membrane expression was then assessed by monitoring
plasma membrane HA immunoreactivity and total cellular
mCherry fluorescence with the use of high-throughput con-
focal microscopy and whole-cell ELISA. For a quantitative
measurement of cell-surface rescue, the ratio between HA
immunoreactivity and the mCherry signal for each assay well
was used as an index for the efficiency of plasma membrane
trafficking following the addition of the rescuing compounds
in order to correct for transfection efficiency and expression
levels. SinceMC4R is linked toGαs, functionality of receptors
was determined bymeasuring the accumulation of the second
messenger cAMP using a FRET (fluorescence resonance
energy transfer)-based immunoassay (LANCE®).
Evidence to support a unique rescue profile
of pharmacological chaperones
Consistent with previously published data, the point
mutations in MC4R chosen for this investigation (V50M,
S58C and I137T) were found to disrupt the normal
trafficking of the receptor and resulted in reduced cell-surface
expression due to retention within the cell [3,7]. Confocal
microscopy (results not shown) and a semi-quantitative
whole-cell ELISA confirmed that the proportion of receptor
expressed at the plasma membrane differs between mutants,
suggesting that the severity of trafficking defects among
intracellularly retainedMC4Rmutants varies. The trafficking
efficiencies of the mutant receptors range from 40% to 80%
compared with those measured for the wild-type receptor
(Figure 1).
The plasma membrane expression of obesity-causing
intracellularly retained mutants of MC4R can be rescued
by the addition of four cell-permeable MC4R antagonists.
Interestingly, the rescue profile of the four compounds differs
between the receptors, including wild-type (Figure 1). Look-
ing at the compounds individually, Compound A has the
most marked effect on S58C and I137T, increasing their cell-
surface expression by approximately 80%. Plasmamembrane
expression of V50M also recovers, by approximately 25%.
Compound B appears to have a significantly higher rescue
efficacy for I137T, increasing its appearance at the plasma
membrane by almost 100% of its basal expression. A 40%
recovery is seen with V50M, and a 60% recovery with S58C.
CompoundC rescues S58C and I137T, increasing cell-surface
expression by more than 100% of their basal level; V50M
shows an increase in plasma membrane expression of 60%.
Lastly, Compound D displays a phenomenal preference in
rescue efficacy for S58C, increasing its cell-surface expression
by over 150%. Lower, but still significant, rescuing effects are
seen with I137T (∼70%) and V50M (∼60%). The efficacy
profiles of the compounds, with respect to plasma membrane
expression, are summarized in Table 1.
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Table 1 Comparison of the ability of compounds A–D to rescue the cell-surface expression of MC4R mutants V50M, S58C and I137T as
measured by whole-cell ELISA
Relative cell-surface expression (% increase from basal)
MC4R + 0.1% DMSO + 10 μM Compound A + 10 μM Compound B + 10 μM Compound C + 10 μM Compound D
Wild-type 25± 2.9 55± 2.7 39± 3.9 48± 3.0 33± 3.1
V50M 18± 1.9 25± 3.9 38± 3.3 62± 4.8 58± 4.6
S58C 11± 2.3 81± 3.3 60± 3.0 114± 2.7 154± 3.2
I137T 11± 3.1 81± 4.8 98± 1.5 103± 4.5 70± 3.5
Figure 2 Functionality of MC4R mutants is restored using four novel pharmacological chaperones with unique rescue efficacy profiles
that do not correlate to potency
(A) The signalling capabilities of mutant human MC4R following rescue to the cell surface. Results are means ± S.E.M.
percentages of NDP-α-MSH ([Nle4, d-Phe7] α-melanocyte-stimulating hormone) agonist-stimulated wild-type (n = 3
performed in triplicate). (B and C) Concentration–effect curves of NDP-α-MSH in the presence of compounds A–D on
rescued V50M expressed in HEK-293 cells (B) and on rescued S58C expressed in HEK-293 cells (C).
These observations were further reinforced using a fully
quantitative high-throughput 96-well fluorescence assay,
which corrects for any differences in transfection efficiency
and expression levels. The ratio of plasma membrane
receptors to total receptor expression can be used as a
direct comparison between wild-type and mutant receptors
under varying conditions, giving a method for assessing the
rescue efficacy of potential pharmacological chaperones.
However, one ought not to overlook the possibility that
such compounds, if antagonists, will stabilize an inactive
conformation of receptor, thereby not only allowing release
to the cell surface, but also simultaneously preventing the
targeting of a properly folded receptor for degradation.
The whole-cell ELISA, although only semi-quantitative,
may nevertheless be a better, but more laborious, measure of
receptor rescue provided that the total receptor levels do not
vary markedly.
Exposure to the putative pharmacological chaper-
ones also increases wild-type MC4R plasma membrane
expression. This is not wholly surprising, as exposure of
the heavily retained wild-type δ opioid receptor to selective
cell-permeable antagonists promotes almost full plasma
membrane expression [8,9], and in our study the receptors
are transiently expressed, meaning a greater level of protein
expression. However, exposure of the wild-type V2R (vaso-
pressin 2 receptor) to the selective cell-permeable antagonist
SR121463Adoes not appear to promote increased cell-surface
expression as measured by FACS [10], although that study
was carried out using stable cell lines, where the expression
levels and receptor pool reserves are likely to be lower. It is
relevant, perhaps, to keep in mind that GPCRs are dynamic
structures that are in a state of equilibrium between active
and inactive conformations. The shifts of this equilibrium
between the two conformations are likely to be different and
produce different consequences for different GPCRs.
Two important controls were included in our study. In
the first, the pharmacological chaperone for the V2R failed
to increase trafficking of the MC4R mutants, indicating
specificity in the effects of compounds A to D. Secondly,
the addition of a high-affinity water-soluble non-permeable
peptide antagonist of the MC4R produced only a very slight
increase in cell-surface expression of the mutants, indicating
that inhibition of down-regulation is not the mechanism of
action of the permeable small-molecule antagonists included
in our study.
The results of our study also show that, following rescue
to the plasma membrane, a degree of functionality could
be restored to two of the three mutants examined in our
study, as demonstrated by a significant increase in cAMP
production upon stimulation with agonist (Figure 2), as
C©The Authors Journal compilation C©2012 Biochemical Society
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well as an increase in the EC50 and Emax values (results
not shown). Interestingly, the rescue efficacy profiles of
the compounds (Figure 1) does not appear to correlate
with their potency at the two rescued receptors (Figure 2).
Restored functionality of mutant receptors suggests that the
cell-surface rescue of intracellularly retained MC4R mutants
using pharmacological chaperones is a promising and exciting
concept that could prove to be a novel therapeutic avenue in
the treatment of early-onset obesity.
Conclusions
The results of our study support the view that different
MC4R point mutations cause specific local misfolding of
the receptors, leading to distinct unstable conformations
that cause intracellular retention. These conformations can
be rescued using MC4R-specific antagonists, presumably by
stabilizing an inactive state of the receptor. The effect varies
with the mutants and the antagonists, either due to a different
energetic profile of the individual mutants or through
differences in the mode of interaction between receptor and
antagonist, or both. The potency of the compounds at rescued
receptors does not appear to correlate with rescuing efficacy.
Recently, a similar study with five cell-permeable
antagonists of MC4R were investigated for cell-surface
rescue of a different cohort of intracellularly retained MC4R
mutants (including S58C) [11]. Differences in the rescuing
efficacies between compounds with each mutant were again
found, supporting the unique rescue profiles for individual
pharmacological chaperones demonstrated in our study. A
degree of functionality of some of the mutants in our study
was restored upon rescue to the cell surface, indicating
potential therapeutic benefits to the use of pharmacological
chaperones in MC4R-related early-onset obesity.
Since all four compounds can promote a significant
proportion of the wild-type receptor to plasma membrane,
pharmacological chaperones could also potentially be used in
obese individuals with normal MC4R.
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